Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI-a pilot study - Characterization of myeloma bone lesions using 18F-FDG-, 18F-fluoride PET/CT and MRI

MUW-Medical University of Vienna,Medizinische Universität Wien0 个研究点开始时间: 2011年11月17日最近更新: 2016年11月14日

适应症

试验速览

暂无简介。

•Ten patients (age: 18-70 years) with diagnosed multiple myeloma stage III by the Durie/Salmon PLUS staging System will be included in the present pilot study. No patients will have received anti-cancer therapy before the start of the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Pregnancy (excluded with a pregnancy test), breast-feeding women, patients that are not able to lie motionless for one hour.
•Patients suffering on cardiac insufficiency and severe hypertonia.
•Patients with acute or chronic renal failure.
•Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 70 years.

发起方

MUW-Medical University of Vienna,Medizinische Universität Wien